Photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: A 30-month multicenter study in Hyogo, Japan
Photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: A 30-month multicenter study in Hyogo, Japan
复制标题
DOI：
10.1007/s10384-009-0741-0
复制
发表时间：
2009-11-01
影响因子：
2.4
通讯作者：
Uenishi, Mamoru
中科院分区：
文献类型：
--
作者：
Honda, Shigeru;Kurimoto, Yasuo;Uenishi, Mamoru
为评价光动力疗法（photodynamic therapy，PDT）治疗年龄相关性黄斑变性（age-related macular degeneration，AMD）的远期疗效，对201例（tAMD 123眼，PCV 84眼）207眼tAMD患者进行了多中心前瞻性研究。对性别、年龄、最佳矫正视力（BCVA）、最大线性尺寸和病变类型进行治疗前因素评价。比较PDT频率、PDT后30个月的BCVA、复发频率和平均复发时间作为治疗后结果，tAMD组PDT后30个月的平均BCVA显著低于PDT前值，但PCV组保持不变。两组PDT频率无差异。多变量分析显示，病变类型是PDT后30个月时与BCVA显著相关的唯一预测因素。PDT治疗后30个月内的复发率在tAMD和PCV组之间无显著差异，而PCV组的PDT效果的平均持续时间显著长于tAMD组。PDT可能对PCV患者有一些优势，但对tAMD患者没有优势。然而，由于PCV经常在PDT后12个月复发，因此治疗后的长期观察至关重要。
To evaluate the long-term effects of photodynamic therapy (PDT) on different phenotypes of age-related macular degeneration (AMD): typical AMD (tAMD) and polypoidal choroidal vasculopathy (PCV).A multicenter prospective study of 207 eyes of 201 patients (tAMD, 123 eyes; PCV, 84 eyes) treated with PDT. Sex, age, best-corrected visual acuity (BCVA), greatest linear dimension, and lesion type were evaluated for pretreatment factors. PDT frequency, BCVA at 30 months post-PDT, frequency of recurrence, and mean recurrence period were compared as posttreatment outcomes.The 30 months post-PDT mean BCVA was significantly lower than the pre-PDT value in the tAMD group, but it remained unchanged in the PCV group. There was no difference in PDT frequency between the two groups. Multivariate analysis revealed that lesion type was the only predicting factor significantly associated with BCVA at 30 months post-PDT. The incidence of recurrence before 30 months post-PDT was not significantly different between the tAMD and PCV groups, whereas the mean duration of the PDT effect was significantly longer in the PCV group than in the tAMD group.PDT may have some advantages for PCV patients, but not for tAMD patients. However, as PCV often recurred 12 months post-PDT, long-term observation after the treatment is crucial.